The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 301–400 of 1,001
Dahal, U. P., Gilbert, A. M., Obach, R. S., Flanagan, M. E., Chen, J. M., Garcia-Irizarry, C., Starr, J. T., Schuff, B., Uccello, D. P., & Young, J. A. (2016) · MedChemComm · doi:10.1039/c6md00017g · Cited by 70
Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry
Trani, J. M. D., Cesco, S. D., O’Leary, R., Plescia, J., do Nascimento, C. J., Moitessier, N., & Mittermaier, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03263-3 · Cited by 85
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Bryan, M. C., & Rajapaksa, N. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00667 · Cited by 77
Fragment-to-Lead Medicinal Chemistry Publications in 2019
Jahnke, W., Erlanson, D. A., de Esch, I. J. P., Johnson, C. N., Mortenson, P. N., Ochi, Y., & Urushima, T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01608 · Cited by 76
Lampson, B. L., & Brown, J. R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435268 · Cited by 74
Birkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 78
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Reversible Covalent Inhibition of a Protein Target
Lee, C., & Grossmann, T. N. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203341 · Cited by 73
Thorarensen, A., Balbo, P., Banker, M. E., Czerwiński, R., Kühn, M., Maurer, T. S., Telliez, J., Vincent, F., & Wittwer, A. J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115865 · Cited by 74
Karges, J., Kalaj, M., Gembický, M., & Cohen, S. M. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202016768 · Cited by 80
Mons, E., Kim, R. Q., van Doodewaerd, B. R., van Veelen, P. A., Mulder, M. P. C., & Ovaa, H. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10513 · Cited by 75
Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Hallenbeck, K., Turner, D., Renslo, A., & Arkin, M. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160719163839 · Cited by 70
An Irreversible Inhibitor of HSP72 that Unexpectedly Targets Lysine‐56
Pettinger, J., Le Bihan, Y., Widya, M., van Montfort, R. L. M., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611907 · Cited by 66
Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Бибикова, Е., Sun, H., Gohdes, M. A., Cardinal, K. A., Sanghvi, M., & Slatter, J. G. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084459 · Cited by 74
“This can result in prolonged pharmacodynamic effects, with the duration of effect related to the time required for target resynthesis (Singh et al., 2011; Barf and Kaptein, 2012).”
BackgroundNguyen, V. S., Loh, X. Y., Wijaya, H., Wang, J., Lin, Q., Lam, Y., Wong, W.-S. F., & Mok, Y. K. (2015) · Journal of Natural Products · doi:10.1021/np5007179 · Cited by 66
Kinnersley, B., Sud, A., Everall, A., Cornish, A. J., Chubb, D., Culliford, R., Gruber, A. J., Lärkeryd, A., Mitsopoulos, C., Wedge, D., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01785-9 · Cited by 73
“Of the remaining 97 genes, 34 are commonly essential, 11 possess concordant lineage specificity, 48 are ligandable by 3D structure and 11 have an existing high-quality probe available (Supplementary Table 13).”
BackgroundRudzińska, M., Dağlıoğlu, C., Savvateeva, L. V., Kacı, F. N., Antoine, R., & Zamyatnin, A. A. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s285852 · Cited by 75
In situ identification of cellular drug targets in mammalian tissue
Pang, Z., Schafroth, M. A., Ogasawara, D., Wang, Y., Nudell, V., Lal, N. K., Yang, D. U., Wang, K., Herbst, D. M., Ha, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.040 · Cited by 72
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 81
Shrimp, J. H., Sorum, A. W., Garlick, J. M., Guasch, L., Nicklaus, M. C., & Meier, J. L. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00385 · Cited by 70
Dahal, U. P., Obach, R. S., & Gilbert, A. M. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400301q · Cited by 70
Milik, S. N., Lasheen, D. S., Serya, R. A. T., & Abouzid, K. A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.023 · Cited by 74
Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase
Kwai, B. X. C., Collins, A. J., Middleditch, M., Sperry, J., Bashiri, G., & Leung, I. K. H. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00301h · Cited by 75
Kang, G., & Romo, D. (2021) · ACS Catalysis · doi:10.1021/acscatal.0c05050 · Cited by 72
Xu, S., Luo, S., Yao, H., Cai, H., Miao, X., Wu, F., Yang, D., Wu, X., Xie, W., Yao, H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00408 · Cited by 70
Dual oxidase: a novel therapeutic target in allergic disease
van der Vliet, A., Danyal, K., & Heppner, D. E. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14158 · Cited by 78
“clearance) and increased duration of action dependent on the biological lifespan of the targeted protein (Singh et al., 2011).”
BackgroundA Structural View on Medicinal Chemistry Strategies against Drug Resistance
Agnello, S., Brand, M., Chellat, M. F., Gazzola, S., & Riedl, R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802416 · Cited by 74
Musharrafieh, R. G., Ma, C., Zhang, J., Hu, Y., Diesing, J. M., Marty, M. T., & Wang, J. (2019) · Journal of Virology · doi:10.1128/jvi.02221-18 · Cited by 72
“The progress curves were fit to a standard exponential equation (equation 1) as described previously (44):”
MethodChemical technology principles for selective bioconjugation of proteins and antibodies
Chauhan, P. S., Ragendu, V., Kumar, M., Molla, R., Mishra, S. D., Basa, S., & Rai, V. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00715d · Cited by 81
Making a Long Journey Short: Alkyne Functionalization of Natural Product Scaffolds
Lehmann, J. C., Wright, M. H., & Sieber, S. A. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201504419 · Cited by 68
Huerta, C., Jiang, X. J., Isaac, T., Bender, C. F., Ferguson, D. A., Probst, B., Swinger, K. K., Stoll, V. S., Thomas, P., Dulubova, I., et al. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.07.026 · Cited by 70
Genetically encoding new bioreactivity
Wang, L. (2016) · New Biotechnology · doi:10.1016/j.nbt.2016.10.003 · Cited by 73
Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90
Cuesta, A., Wan, X., Burlingame, A. L., & Taunton, J. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b09684 · Cited by 66
Rowbottom, M. W., Bain, G., Calderon, I., Lasof, T., Lonergan, D. G., Lai, A. G., Huang, F., Darlington, J. V., Prodanovich, P., Santini, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00345 · Cited by 71
Thiol Probes To Detect Electrophilic Natural Products Based on Their Mechanism of Action
Castro-Falcón, G., Hahn, D., Reimer, D., & Hughes, C. C. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00924 · Cited by 67
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome
Rao, S., Gurbani, D., Du, G., Everley, R. A., Browne, C. M., Chaikuad, A., Tan, L., Schröder, M., Gondi, S., Ficarro, S. B., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.021 · Cited by 64
“Covalent kinase inhibitors present several potential advantages over their reversible counterparts including (1) improved selectivity over other targets due to binding of non-conserved cysteine residues, (2) stronger potency owing to high-affinity binding between drug and target, (3) beneficial pharmacodynamics from i…”
BackgroundGersch, M., Kolb, R., Alte, F., Groll, M., & Sieber, S. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4082793 · Cited by 66
Izquierdo-Serra, M., Bautista-Barrufet, A., Trapero, A., Garrido‐Charles, A., Díaz‐Tahoces, A., Camarero, N., Pittolo, S., Valbuena, S., Perez‐Jiménez, A., Gay, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12221 · Cited by 72
Corso, A. D., Catalano, M., Schmid, A. S., Scheuermann, J., & Neri, D. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811650 · Cited by 71
Baggio, C., Udompholkul, P., Gambini, L., Salem, A. F., Jossart, J. N., Perry, J. J. P., & Pellecchia, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01108 · Cited by 68
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 71
Applications of covalent chemistry in targeted protein degradation
Lu, D., Yu, X., Lin, H., Cheng, R., Monroy, E. Y., Qi, X., Wang, M. C., & Wang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00362g · Cited by 72
Kynurenine Aminotransferase Isozyme Inhibitors: A Review
Nematollahi, A., Sun, G., Jayawickrama, G. S., & Church, W. B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060946 · Cited by 67
Xu, S., Aguilar, A., Xu, T., Zheng, K., Huang, L., Stuckey, J. A., Chinnaswamy, K., Bernard, D., Fernández‐Salas, E., Liu, L., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201711828 · Cited by 68
Vu, H., Pedro, L., Mak, T., McCormick, B. P., Rowley, J., Liu, M., Capua, A. D., Williams‐Noonan, B. J., Pham, N. B., Pouwer, R. H., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00197 · Cited by 67
Mapping, Structure and Modulation of PPI
Martino, E., Chiarugi, S., Margheriti, F., & Garau, G. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.718405 · Cited by 65
“However, due to the natural driving force mediating PPI, the stabilization of protein complexes may represent a promising modulation strategy for therapeutic intervention (Figures 1C,D) (Singh et al., 2011; O’Connell et al., 2019; Sijbesma et al., 2020).”
BackgroundThe anti‐inflammatory compound BAY‐11‐7082 is a potent inhibitor of protein tyrosine phosphatases
Krishnan, N., Bencze, G., Cohen, P., & Tonks, N. K. (2013) · The FEBS Journal · doi:10.1111/febs.12283 · Cited by 62
Catalytic Metallodrugs: Substrate‐Selective Metal Catalysts as Therapeutics
Yu, Z., & Cowan, J. A. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701714 · Cited by 69
The aryl hydrocarbon receptor (AhR) as a breast cancer drug target
Baker, J. R., Sakoff, J. A., & McCluskey, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21645 · Cited by 73
“It is postulated that the Michael acceptor capacity of the acrylonitrile moiety, forming covalent adducts, is pivotal to the observed specificity of ANI‐7 and associated analogs.(164,165) The 4‐acetamide derivative 32 (Figure 13) was the most potent of the phenylacrylonitriles reported to date, with nanomolar potency…”
BackgroundTargeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
Burger, J. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283589950 · Cited by 73
Docking-Based Virtual Screening of Covalently Binding Ligands: An Orthogonal Lead Discovery Approach
Schröder, J., Klinger, A., Oellien, F., Marhöfer, R. J., Duszenko, M., & Selzer, P. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3013932 · Cited by 64
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 70
(2022) · doi:10.1016/j.chempr.2022.07.012 · Cited by 64
“Covalent small-molecule drugs have been shown to possess enhanced potency, prolonged duration of action, and the ability to mitigate drug resistance.(16,17) We thus envisioned that protein drugs able to bind the virus irreversibly in covalent mode would be highly desirable to attain potent and complete inhibition of v…”
Toward the First Class of Suicide Inhibitors of Kallikreins Involved in Skin Diseases
Tan, X., Soualmia, F., Furio, L., Renard, J.-F., Kempen, I., Qin, L., Pagano, M., Pirotte, B., Amri, C. E., Hovnanian, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500988d · Cited by 64
Campuzano, I. D. G., San Miguel, T., Rowe, T., Onea, D., Cee, V. J., Arvedson, T., & McCarter, J. D. (2016) · SLAS Discovery · doi:10.1177/1087057115621288 · Cited by 63
Discovery of a novel covalent non-β-lactam inhibitor of the metallo-β-lactamase NDM-1
Christopeit, T., Albert, A., & Leiros, H. S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.064 · Cited by 63
Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz‐Fademrecht, C., Zahedi, R. P., Bauer, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201605011 · Cited by 65
Heppner, D. E., Hristova, M., Dustin, C. M., Danyal, K., Habibovic, A., & van der Vliet, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.749028 · Cited by 66
Covalent inhibition of protein tyrosine phosphatases
Ruddraraju, K. V., & Zhang, Z. (2017) · Molecular BioSystems · doi:10.1039/c7mb00151g · Cited by 68
Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 63
Zimmermann, G., Schultz-Fademrecht, C., Küchler, P., Murarka, S., Ismail, S., Triola, G., Nussbaumer, P., Wittinghofer, A., & Waldmann, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500632s · Cited by 62
Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era
Taboureau, O., Baell, J. B., Fernández‐Recio, J., & Villoutreix, B. O. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.007 · Cited by 69
Multiplexed Thiol Reactivity Profiling for Target Discovery of Electrophilic Natural Products
Tian, C., Sun, R., Liu, K., Fu, L., Liu, X., Zhou, W., Yang, Y., & Yang, J. H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.022 · Cited by 63
Förster, M., Chaikuad, A., Dimitrov, T., Döring, E., Holstein, J., Berger, B., Gehringer, M., Ghoreschi, K., Müller, S., Knapp, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00571 · Cited by 66
Docking of Covalent Ligands: Challenges and Approaches
Sotriffer, C. (2018) · Molecular Informatics · doi:10.1002/minf.201800062 · Cited by 63
Redox regulation of tyrosine kinase signalling: more than meets the eye
Dustin, C. M., Heppner, D. E., Lin, M.-C. J., & van der Vliet, A. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz085 · Cited by 69
“(91, 92) and for inhibition by other thiol-reactive electrophiles such as acrolein (61).”
BackgroundDevelopment of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Protein Labeling and Crosslinking by Covalent Aptamers
Tivon, Y., Falcone, G. N., & Deiters, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101174 · Cited by 65
Büchold, C., Hils, M., Gerlach, U., Weber, J., Pelzer, C., Heil, A., Aeschlimann, D. P., & Pasternack, R. (2022) · Cells · doi:10.3390/cells11101667 · Cited by 61
“While a “resurgence” of such suicide inhibitors is recognized to a certain extent [56], reluctance is still prevalent within the pharmaceutical industry due to potential drug-induced injury.”
BackgroundEpidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 62
Compounds targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria
Landeta, C., Blazyk, J. L., Hatahet, F., Meehan, B. M., Eser, M., Myrick, A., Bronstain, L., Minami, S., Arnold, H. K., Ke, N., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1752 · Cited by 61
The Mechanism of Caseinolytic Protease (ClpP) Inhibition
Gersch, M., Gut, F., Korotkov, V. S., Lehmann, J., Böttcher, T., Rusch, M., Hedberg, C., Waldmann, H., Klebe, G., & Sieber, S. A. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201204690 · Cited by 61
Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?
Chatterjee, P., Botello‐Smith, W. M., Zhang, H., Qian, L., Alsamarah, A., Kent, D., Lacroix, J. J., Baudry, M., & Luo, Y. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08938 · Cited by 65
Golldack, A., Henke, B., Bergmann, B., Wiechert, M., Erler, H., Soares, A. B., Spielmann, T., & Beitz, E. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006172 · Cited by 60
Ube2V2 Is a Rosetta Stone Bridging Redox and Ubiquitin Codes, Coordinating DNA Damage Responses
Zhao, Y., Long, M. J. C., Wang, Y., Zhang, S., & Aye, Y. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00556 · Cited by 66
Nuisance compounds in cellular assays
Dahlin, J. L., Auld, D. S., Rothenaigner, I., Haney, S., Sexton, J. Z., Nissink, J. W. M., Walsh, J. J., Lee, J. A., Strelow, J. M., Willard, F. S., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.021 · Cited by 66
“The success of modern targeted covalent modulators (Singh et al., 2011) may also inspire more primary screening of compounds with covalent warheads.”
BackgroundBicyclic Cyclohexenones as Inhibitors of NF-κB Signaling
Hexum, J. K., Tello‐Aburto, R., Struntz, N. B., Harned, A. M., & Harki, D. A. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300034a · Cited by 59
Kang, Y., Taldone, T., Patel, H. J., Patel, P. D., Rodina, A., Gozman, A., Maharaj, R., Clement, C. C., Patel, M. R., Brodsky, J. L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401551n · Cited by 59
Natural products as kinase inhibitors
Liu, J., Hu, Y., Waller, D. L., Wang, J., & Liu, Q. (2012) · Natural Product Reports · doi:10.1039/c2np00097k · Cited by 58
The Increasing Role of QM/MM in Drug Discovery
Lodola, A., & Vivo, M. D. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398312-1.00011-1 · Cited by 66
Covalent peptides and proteins for therapeutics
Berdan, V. Y., Klauser, P. C., & Wang, L. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115896 · Cited by 62
Panek, D., Więckowska, A., Jończyk, J., Godyń, J., Bajda, M., Wichur, T., Pasieka, A., Knez, D., Pišlar, A. H., Korábečný, J., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00461 · Cited by 58
Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange
Nnadi, C. I., Jenkins, M. L., Gentile, D. R., Bateman, L. A., Zaidman, D., Balius, T. E., Nomura, D. K., Burke, J. E., Shokat, K. M., & London, N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00399 · Cited by 57
Delre, P., Caporuscio, F., Saviano, M., & Mangiatordi, G. F. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.594009 · Cited by 60
“A covalent mechanism of action, indeed, leads to several advantages in terms of potency, duration of action, and selectivity (Singh et al., 2011) and therefore is highly desirable for COVID-19 treatment.”
BackgroundCovalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects
Klauser, P. C., Chopra, S., Cao, L., Bobba, K. N., Yu, B., Seo, Y., Chan, E., Flavell, R. R., Evans, M. J., & Wang, L. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00288 · Cited by 61
Kawano, M., Murakawa, S., Higashiguchi, K., Matsuda, K., Tamura, T., & Hamachi, I. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08740 · Cited by 63
Mass Spectrometric and Functional Aspects of Drug–Protein Conjugation
Tailor, A., Waddington, J. C., Meng, X., & Park, B. K. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00147 · Cited by 62
Using Protein-Confined Proximity To Determine Chemical Reactivity
Kobayashi, T., Hoppmann, C., Yang, B., & Wang, L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08656 · Cited by 59
McCune, C. D., Beio, M. L., Sturdivant, J. M., de la Salud‐Bea, R., Darnell, B. M., & Berkowitz, D. B. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04690 · Cited by 58
The Proteome‐Wide Potential for Reversible Covalency at Cysteine
Senkane, K., Vinogradova, E. V., Suciu, R. M., Crowley, V. M., Zaro, B. W., Bradshaw, J. M., Brameld, K. A., & Cravatt, B. F. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905829 · Cited by 56
Frequent hitters: nuisance artifacts in high-throughput screening
Yang, Z., He, J.-H., Lü, A., Hou, T., & Cao, D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.014 · Cited by 69
Xie, F., Zhang, H., Zheng, C., & Shen, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106567 · Cited by 59
The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions
Pichler, W. J. (2021) · Allergy · doi:10.1111/all.14962 · Cited by 64
Hirose, Y., Shindo, N., Mori, M., Onitsuka, S., Isogai, H., Hamada, R., Hiramoto, T., Ochi, J., Takahashi, D., Ueda, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01081 · Cited by 59
c-JunN-terminal kinase inhibitors: a patent review (2010 – 2014)
Gehringer, M., Muth, F., Koch, P., & Laufer, S. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1039984 · Cited by 65
Balancing novelty with confined chemical space in modern drug discovery
Medina‐Franco, J. L., Martínez‐Mayorga, K., & Meurice, N. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.872624 · Cited by 58
How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor‐Williams, E., & Rowley, C. N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00454 · Cited by 58
Tichá, A., Stanchev, S., Vinothkumar, K. R., Mikles, D. C., Pachl, P., Began, J., Škerle, J., Švehlová, K., Nguyen, M. T. N., Verhelst, S. H. L., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.007 · Cited by 53
Kharenko, O. A., Patel, R. G., Brown, S. D., Calosing, C., White, A., Lakshminarasimhan, D., Suto, R. K., Duffy, B. C., Kitchen, D. B., McLure, K. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00666 · Cited by 52
Structure-Based Design of Covalent Siah Inhibitors
Stebbins, J. L., Santelli, E., Feng, Y., De, S. K., Purves, A., Motamedchaboki, K., Wu, B., Ronai, Z. A., Liddington, R., & Pellecchia, M. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.008 · Cited by 56
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.